Role of gefitinib (G) in heavily pretreated non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Tamburini, E.
Tassinari, D.
Pasquini, E.
Papi, M.
Possenti, C.
Drudi, F.
Castellani, C.
Santelmo, C.
Carloni, F.
Ravaioli, A.
机构：
[1] Dept Oncol, Rimini, Italy
[2] Dept Oncol, Cattolica, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19102
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Role of chemokines in resectable non-small cell lung cancer (NSCLC)
    Drosslerova, M.
    Sterclova, M.
    Vasakova, M.
    Taskova, A.
    Hytych, V.
    Horazd'ovsky, P.
    Richterova, E.
    Smetakova, M.
    Havel, L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [22] Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)
    F Cappuzzo
    S Bartolini
    G L Ceresoli
    S Tamberi
    A Spreafico
    L Lombardo
    V Gregorc
    L Toschi
    C Calandri
    E Villa
    L Crinò
    British Journal of Cancer, 2004, 90 : 82 - 86
  • [23] Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)
    Cappuzzo, F
    Bartolini, S
    Ceresoli, GL
    Tamberi, S
    Spreafico, A
    Lombardo, L
    Gregorc, V
    Toschi, L
    Calandri, C
    Villa, E
    Crinò, L
    BRITISH JOURNAL OF CANCER, 2004, 90 (01) : 82 - 86
  • [24] Molecular characteristics of non-small cell lung cancer (NSCLC) patients sensitive to gefitinib.
    Pao, W
    Zakowski, M
    Cordon-Cardo, C
    Ben-Porat, L
    Kris, MG
    Miller, VA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 623S - 623S
  • [25] Pharmacokinetics of gefitinib predicts the antitumor activity for advanced non-small cell lung cancer (NSCLC).
    Nakamura, Y.
    Sano, K.
    Fukuda, M.
    Takatani, H.
    Nagashima, S.
    Kinoshita, A.
    Fukuda, M.
    Soda, H.
    Oka, M.
    Kohno, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 81S - 81S
  • [26] Pharmacokinetics of gefitinib predicts the antitumor activity for advanced non-small cell lung cancer (NSCLC)
    Iida, Tetsuya
    Nakamura, Yoichi
    Fukuda, Masaski
    Takatani, Hiroshi
    Nagashima, Seiji
    Kinoshita, Akitoshi
    Fukuda, Minoru
    Soda, Hiroshi
    Oka, Mikio
    Kohno, Shigeru
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S462 - S462
  • [27] Gefitinib in patients with non-small cell lung cancer (NSCLC): The Royal Marsden experience.
    Parton, M
    Maisey, N
    Banerjee, S
    Harper-Wynne, C
    Sumpter, K
    Ashley, S
    Eisen, T
    Obrien, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 641S - 641S
  • [28] Factors predicting the efficacy of gefitinib in patients with advanced non-small cell lung cancer (NSCLC).
    Kishi, K
    Homma, S
    Miyamoto, A
    Sakamoto, S
    Motoi, N
    Yoshimura, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 644S - 644S
  • [29] Gefitinib in heavily pretreated non small cell lung cancer: Results of the expanded access program in Eastern France.
    Spaeth, D
    Deplanque, G
    Favrot, N
    Paillot, N
    Lang, MP
    Cuguiliere, A
    Seigneur, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 696S - 696S
  • [30] Gefitinib ('Iressa', ZD1839) in heavily pretreated patients with metastatic non-small-cell lung cancer
    Martín-Algarra, S
    Gurpide, A
    Lopez-Picazo, JM
    BRITISH JOURNAL OF CANCER, 2003, 89 : S30 - S30
12345